Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional) (PAR-24-110)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed) (PAR-24-203)

Sponsor: National Institute of Neurological Disorders and Stroke, National Institute on Aging

Award: Application budgets are limited to $500,000 in direct costs/year and need to reflect the actual needs of the proposed project. The maximum project period is five years.

Due Date: October 04, 2024.

Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required) (PA-24-184)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) (PA-24-185)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Basic Experimental Studies with Humans Required) (PA-24-186)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Feasibility Trials of the NIH Music-based Interventions Toolkit for Brain Disorders of Aging (R34 Clinical Trial Required) (PAR-24-168)

Sponsor: National Center for Complementary and Integrative Health, National Institute on Aging

Award: This R34 is limited to direct costs requests of up to $450,000 over the entire project period. Although variations from year to year are permissible, in no case may any year be more than $225,000 in direct costs. The maximum project period is 3 years.

Due Date: Multiple due dates; see announcement.

Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Amyloid Beta Immunotherapy (R01 - Clinical Trial Not Allowed) (PAR-24-198)

Sponsor: National Institute of Neurological Disorders and Stroke, National Institute on Aging

Award: Application budgets are limited to no more than $500,000 in direct costs per year and need to reflect the actual needs of the proposed project. The maximum project period is five years.

Due Date: October 04, 2024.

Notice of Special Interest (NOSI): Administrative Supplements to Promote Diversity for NINDS ADRD Awardees (NOT-NS-24-071)

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Due Date: Notice expires February 15, 2027.

Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed) (RFA-TR-24-023)

Sponsor: National Center for Advancing Translational Sciences (NCATS)

Award: The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

Due Date: Multiple due dates; see announcement.

Mechanistic and Hemodynamic Basis of Diffuse White Matter Disease in Vascular Contributions to Cognitive Impairment and Dementia (VCID)(R01 - Clinical Trial Not Allowed) (PAR-24-196)

Sponsor: National Institute of Neurological Disorders and Stroke, National Institute on Aging

Due Date: October 4, 2024

Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional) (PAR-24-206)

Sponsor: National Institutes of Health

Award: Applicants may request up to $1 million in direct costs/year. Applicants may request up to 5 years of support.

Due Date: Application due August 13, 2024. Letter-of-intent due 30 days prior to the application due date.

The Alzheimer's Drug Discovery Foundation (ADDF) Therapeutics Funding Programs

Sponsor: The Alzheimer's Drug Discovery Foundation (ADDF)

Due Date: Multiple due dates; see announcement.

Michelson Prizes: Next Generation Grants

Sponsor: The Michelson Medical Research Foundation and the Human Immunome Project

Award: The $150,000 Michelson Prizes are awarded annually to support early-career investigators working to advance human immunology, vaccine discovery, and immunotherapy research for major global diseases.

Due Date: June 9, 2024

Accelerating Drug Discovery for FTD

Sponsor: The Alzheimer’s Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD)

Award: $300,000-$350,000 based on stage and scope of research. Slightly higher budgets can be considered. One year with potential for follow-on funding.

Due Date: Letter of intent due May 13th, 2024. Invited full proposal due July 22nd, 2024.

ADDF-Harrington Scholar Program

Sponsor: The Alzheimer’s Drug Discovery Foundation (ADDF) and the Harrington Discovery Institute.

Award: This award provides funding and project support by a team of pharmaceutical industry experts through a collaboration between the Alzheimer’s Drug Discovery Foundation (ADDF) and the Brain Health Medicines Centers of the Harrington Discovery Institute. The award typically entails up to $600,000 over 2 years.

Due Date: Letter of intent due June 3, 2024, 5:00 PM EDT. Full proposal due August 26, 2024, 5:00 PM EDT.